Advertisement
Advertisement
U.S. markets open in 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.8598-0.0252 (-2.85%)
At close: 04:00PM EST
0.8650 +0.01 (+0.60%)
Pre-Market: 09:13AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close0.8850
Open0.8700
Bid0.8437 x 4000
Ask0.8751 x 3000
Day's Range0.8100 - 0.9000
52 Week Range0.7900 - 7.0200
Volume590,353
Avg. Volume624,056
Market Cap39.17M
Beta (5Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-0.4990
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PLX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Protalix BioTherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/04/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more
  • PR Newswire

    Protalix BioTherapeutics Issues 2021 Letter to Stockholders

    Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.

  • Zacks Small Cap Research

    PLX: Third Quarter Update

    By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 3Q:21 financial and operational results in a November 15, 2021 press release and filing of Form 10-Q . Promulgation of the reports was followed by a pre-market conference call which discussed recent achievements. Operational

  • PR Newswire

    Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update

    Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2021 and provided a financial and business update on recent corporate, clinical and regulatory developments.

Advertisement
Advertisement